The PD-1/PD-L1 Race in China
Since its approval as the first PD-1/PD-L1 inhibitor, on September 4, 2014, Keytruda has stood on the top of the heap and dominated attention across the spectrum of industry watchers. At present, the competition in this field is especially fierce. All five PD-1/PD-L1 inhibitors on the market are actively expanding their territories and rapidly pushing …